MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity

Metastasis to vital organs remains the leading cause of cancer-related deaths, emphasizing an urgent need for actionable targets in advanced-stage cancer. The role of mitochondrial Rho GTPase 2 (MIRO2) in prostate cancer growth was recently reported; however, whether MIRO2 is important for additional steps in the metastatic cascade is unknown. Here, we show that knockdown of MIRO2 ubiquitously reduces tumor cell invasion in vitro and suppresses metastatic burden in prostate and breast cancer mouse models. Mechanistically, depletion of MIRO2's binding partner-unconventional myosin 9B (MYO9B)-reduces tumor cell invasion and phenocopies MIRO2 depletion, which in turn results in increased active RhoA. Furthermore, dual ablation of MIRO2 and RhoA fully rescues tumor cell invasion, and MIRO2 is required for MYO9B-driven invasion. Taken together, we show that MIRO2 supports invasion and metastasis through cooperation with MYO9B, underscoring a potential targetable pathway for patients with advanced disease.

Authors

Institutions

Publication Details

Journal
Cell Reports
Published
2024-12-24
DOI
https://doi.org/10.1016/j.celrep.2024.115120
Citations
4
Primary Topic
Signaling Pathways in Disease
Type
article
Field-Weighted Citation Impact
0.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity

Valentina Vaira, Masoom Raza, Alessandro Del Gobbo, Colm M. Morrissey et al.
4 citations
Cell Reports
Signaling Pathways in Disease
0.94
article

MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity

Valentina Vaira, Masoom Raza, Alessandro Del Gobbo, Colm M. Morrissey, Dillon P. Boulton, Heide L. Ford, A. Palleschi, Marco Locatelli, Etienne Danis, Connor J. Hughes, Rytis Prekeris, M. Cecilia Caino, Andrew J. Neumann, Stephen C. Purdy, John Meshki, Raymundo Lerma
article en
4 citations

Abstract

Metastasis to vital organs remains the leading cause of cancer-related deaths, emphasizing an urgent need for actionable targets in advanced-stage cancer. The role of mitochondrial Rho GTPase 2 (MIRO2) in prostate cancer growth was recently reported; however, whether MIRO2 is important for additional steps in the metastatic cascade is unknown. Here, we show that knockdown of MIRO2 ubiquitously reduces tumor cell invasion in vitro and suppresses metastatic burden in prostate and breast cancer mouse models. Mechanistically, depletion of MIRO2's binding partner-unconventional myosin 9B (MYO9B)-reduces tumor cell invasion and phenocopies MIRO2 depletion, which in turn results in increased active RhoA. Furthermore, dual ablation of MIRO2 and RhoA fully rescues tumor cell invasion, and MIRO2 is required for MYO9B-driven invasion. Taken together, we show that MIRO2 supports invasion and metastasis through cooperation with MYO9B, underscoring a potential targetable pathway for patients with advanced disease.

Cell ReportsVol. 44(1)
University of Washington (US), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Colorado Cancer Center (US), University of Colorado Anschutz Medical Campus (US), University of Colorado Denver (US)
U.S. Department of Defense, Boettcher Foundation, University of Washington, National Institutes of Health, Cancer Center, University of Colorado, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 24%
Signaling Pathways in Disease
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.